---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-262210"
form_type: "8-K"
ticker: "ELVN"
cik: "0001672619"
company_name: "Enliven Therapeutics, Inc."
filed_at: "2022-10-13T23:59:59+00:00"
generated_at: "2026-06-23T03:51:26.432992+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Imara to merge with Enliven; Enliven stockholders to own ~84% of combined company

## Summary
- Enliven valued at $324.6M plus $164.5M financing; Imara valued at net cash plus $10M.
- Pre-merger Imara stockholders to own ~16% of combined co; CVRs tied to asset sale/IMR-261.
- Concurrent $164.5M Enliven PIPE; closing conditioned on Imara asset sale, HSR, stockholder votes.
- Board: 8 Enliven designees, 1 Imara (CEO Rahul Ballal); reverse stock split planned.
- Termination fees: Imara pays $3M, Enliven pays $9.75M under specified conditions.

## SEC filing metadata
- accession: 0001193125-22-262210
- form_type: 8-K
- ticker: ELVN
- cik: 0001672619
- company_name: Enliven Therapeutics, Inc.
- filed_at: 2022-10-13T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672619/000119312522262210/0001193125-22-262210-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672619/000119312522262210/d343665d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-262210
- JSON: https://secwatch.observer/filing/0001193125-22-262210.json
- Plain text: https://secwatch.observer/filing/0001193125-22-262210.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.